Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Cancer

Liquid biopsy predicts treatment resistance in advanced prostate cancer

Patients with prostate cancer could be selected for alternative treatments using liquid biopsy, researchers say.

Researchers say that ‘liquid biopsy’ could potentially be used to select patients  with advance prostate cancer for alternative treatments, but this would need validation in a randomised trial. In the image, light micrograph of prostate cancer cells

Source: Nancy Kedersha / Science Photo Library

Patients with prostate cancer who had abberations in the androgen receptor gene before treatment had significantly poorer progression-free and overall survival

Obtaining metastatic tumour samples in order to understand the molecular events that result in resistance to therapies for advanced prostate cancer can be challenging.

Now, researchers from the Institute of Cancer Research in London have used a blood test that detects circulating tumour DNA (ctDNA), which has shed from tumours, to identify the genetic mutations associated with resistance to the second-line therapy abiraterone.

The results of the study, published in Science Translational Medicine[1] (online, 4 November 2015), found that among 97 patients, those with abberations in the androgen receptor gene before treatment had significantly poorer progression-free and overall survival. Men with ctDNA concentrations above the median also had a poorer prognosis.

The researchers say ‘liquid biopsy’ could be used to select patients for alternative treatments, such as chemotherapy or radiotherapy, but this would need validation in a randomised controlled trial.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2015.20200062

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • Researchers say that ‘liquid biopsy’ could potentially be used to select patients  with advance prostate cancer for alternative treatments, but this would need validation in a randomised trial. In the image, light micrograph of prostate cancer cells

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.